Benign Prostatic Hyperplasia Prostate Treatment Market Size & Share, by Treatment Type (Drug, Surgical Treatment); Therapeutic Class {BPH Devices (Transurethral RF Thermal Therapy, Suture Base Implant), BPH Drugs (Alpha Blocker, Muscarinic Receptor Antagonist, 5-Alpha Reductase Inhibitors)}; Distribution Channel (Pharmacies, Online, Institutional Sales) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4218
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Benign Prostatic Hyperplasia Prostate Treatment Market size is poised to cross USD 13 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of benign prostatic hyperplasia (BPH) prostate treatment was over USD 7 Billion. The growth of the market can primarily be ascribed to the growing rate of BPH surgical treatment since it can cost one’s life. Moreover, it is a disorder that is generally observed in men around the world, it is anticipated to increase the market’s growth. For instance, nearly 200,000 prostatectomy procedures are carried every year for benign diseases in the United States.

Global benign prostatic hyperplasia (BPH) prostate treatment market trends such as, the higher prevalence of benign prostatic hyperplasia (BPH) and rising awareness of the disease are estimated to hike the growth of the market over the forecast period. Moreover, benign prostatic hyperplasia has been accepted as an increasing health problem among aged men, and it is predicted to increase the market’s growth in the upcoming years.  For instance, benign prostatic hyperplasia becomes more prevalent in men after the age of 40 with a prevalence rate of approximately 10% to 65% across the globe.


Global-Benign-Prostatic-Hyperplasia-Prostate-Treatment-Market
Get more information on this report: Request Free Sample PDF

Benign Prostatic Hyperplasia Prostate Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Geriatric Population- As per the figures demonstrated by the World Bank, it is estimated that the geriatric population reached 747,238,580 in 2021. Benign prostatic hyperplasia (BPH) prostate is a disease that occurs in older man. Since the number of geriatrics is high, the probability for the prevalence of benign prostatic hyperplasia (BPH) rises. BPH can be a severe health condition that requires immediate medical care, which is anticipated to increase the growth of the global benign prostatic hyperplasia (BPH) prostate treatment market.
  • Higher Prevalence of Benign Prostatic Hyperplasia (BPH)-There is a high prevalence of benign prostatic hyperplasia owing to different factors such as obesity, aging male population, and physical activity, and it is predicted to drive the market’s growth over the forecast period. Based on the report published by the National Institute of Diabetes and Digestive and Kidney Diseases, it is demonstrated that around 50% of men aged between 51 to 60 live with benign prostatic hyperplasia.
  • Developing Medical Technology Across the Globe - As of 2022, the growth of global medical technology was estimated to increase by approximately 4% per year.
  • Spiking Cases of Urinary Tract Infection - For instance, in the United States, approximately 0.9 million cases of UTIs are diagnosed every year.
  • Increasing Healthcare Expenditure Per Capita- Improvement in the healthcare infrastructure, followed by the increase in the healthcare expenditure around the word, are making the upgraded treatment with better technology available for the patients. Therefore, it is expected to surge the growth of the global benign prostatic hyperplasia (BPH) prostate treatment market. In 2019, the healthcare expenditure across the globe was estimated to be around 1000 U.S. dollars per capita.

Challenges

  • Possibility of Side-Effects of BPH Drugs - There can be significant side-effects of BPS drugs that can play as significant restraint factors. The side effects of benign prostatic hyperplasia (BPH) prostate treatment are dizziness, dry mouth, nasopharyngitis, pruritus, micturition difficulties, constipation, and others. This is expected to hamper the growth of the market in the upcoming years.
  • Stringent Government Regulations Regarding the Sales and Consumption of Medicines
  • Lack of Awareness of the Disease in Developing Countries

Benign Prostatic Hyperplasia Prostate Treatment Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

6%

Base Year Market Size (2022)

USD 7.0 Billion

Forecast Year Market Size (2035)

USD 13.0 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Benign Prostatic Hyperplasia Prostate Treatment Segmentation

The global benign prostatic hyperplasia (BPH) prostate treatment market is segmented and analyzed for demand and supply by treatment type into drug, and surgical treatment. Out of these, the drug treatment segment is projected to witness noteworthy growth over the forecast period. The growth of the drug treatment segment is attributed to the rising consumption of drugs across the world. There are more than 20,000 prescription drugs approved in the United States for marketing. Also, about 70% of U.S. adults take prescription drugs. Also, the increment in sales of medicines from pharmacies is considered to be another growth factor for the segment. For instance, the sales of pharmacies and drug stores were projected to be around USD 300 billion in the USA in 2020.

Moreover, the global benign prostatic hyperplasia (BPH) prostate treatment market is further segmented by therapeutic class into BPH devices and BPH drugs. Out of these, the BPH drugs segment is predicted to hold the largest share over the forecast period. This can be attributed to the increased awareness related to the use of alpha blocker for relaxing the bladder neck, which helps the urine to flow in much easier manner. Benign prostatic hyperplasia treatment is the most general treatment for the men suffering with mild to moderate benign prostatic hyperplasia (BPH) prostate symptoms, and it is projected to surge the segment’s growth in the market.

.Our in-depth analysis of the global benign prostatic hyperplasia (BPH) prostate treatment market includes the following segments:

                    By Treatment Type

  • Drug Treatment
  • Surgical Treatment

                   By Therapeutic Class

  • BPH Devices
  • Transurethral RF Thermal Therapy
  • Suture Base Implant
  • Others
  • BPH Drugs
  • Alpha Blocker
  • Muscarinic Receptor Antagonist
  • 5-Alpha Reductase Inhibitors

                  By Distribution Channel

  • Pharmacies
  • Online
  • Institutional Sales

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Benign Prostatic Hyperplasia Prostate Treatment Industry - Regional Synopsis

North America Market Forecast

The North America market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of market can be ascribed to the rising geriatric population, an increasing unhealthy lifestyle, and a higher prevalence of benign prostatic hyperplasia. As per the data released by the World Bank, it was represented that in 2021, the geriatric population in the USA reached 56,545,938. Furthermore, the presence of major key players, rapidly growing healthcare infrastructure of the region, coupled with the surge in novel drug delivery systems are further projected to influence the growth of the market positively over the forecast period.

Asia Pacific Market Forecast

On the other hand, the Asia Pacific region is expected to witness the fastest growth in the upcoming years, backed by the surging urological disorders cases, rising investment in the research and development for better medical facilities, and increasing demand for the benign prostatic hyperplasia (BPH) prostate treatment in the region. Furthermore, the growing population is further projected to surge the market’s growth in the region.

Research Nester
Global-Benign-Prostatic-Hyperplasia-Prostate-Treatment-Market-size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Cardinal Health Inc.
    • NxThera, Inc.
    • Veru, Inc.
    • Teleflex Incorporated
    • Eli Lily & Company
    • Sanofi S.A.
    • GSK plc
    • Mylan N.V.
    • AbbVie Inc.

In-the-news

In The News

  • Teleflex Incorporated announced the results of research studies regarding the efficacy and safety of UroLift systems. The system is developed for men diagnosed with benign prostatic hyperplasia (BPH) and median lobe obstruction.

  • Veru Inc. announced that it has received approval by the United States Food and Drug Administration (FDA) for its finasteride and tadalafil capsules, known as ENTADFI, which is used to treat urinary tract symptoms caused as a result of an enlarged prostate, commonly known as BPH.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4218
  • Published Date: Feb 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher prevalence of benign prostatic hyperplasia (BPH), developing medical technology across the globe, increasing healthcare expenditure per capita, and spiking cases of urinary tract infection are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Government initiatives regarding the sales and consumption of medicines, and lack of awareness of the disease in developing countries are estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Cardinal Health Inc., NxThera, Inc., Veru, Inc., Teleflex Incorporated, Eli Lily & Company, Sanofi S.A., GSK plc, Mylan N.V., AbbVie Inc., Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by therapeutic class, distribution channel, treatment type, and by region

The drug treatment segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Benign Prostatic Hyperplasia Prostate Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying